Breaking news on Genetics & Genomics business, policy & funding.
The firm has opened a $10 million Series A financing round that it expects to close in late summer to support running clinical studies for its assay.
The company attributed the revenue decline in part to working capital restraints and long manufacturing lead times, which are being addressed currently.
Saga has developed a digital PCR-based technology that it says can detect circulating tumor DNA with a mutational allele frequency of 0.001 percent.
Atrin will use Predictive's GenDB databases and women's health biobank to study germline mutations in DNA damage and response inhibitor pathways.
CEO Prahlad Singh said the firm is developing a PCR- and antibody-based assay for the novel coronavirus 2019-nCoV and is working with the Chinese NMPA.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.